KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Short term Debt (2018 - 2026)

Aquestive Therapeutics has reported Short term Debt over the past 8 years, most recently at $10.0 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 38338.46% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, up 38338.46%, while the annual FY2025 figure was $10.0 million, 38338.46% up from the prior year.
  • Short term Debt for Q4 2025 was $10.0 million at Aquestive Therapeutics, up from $6.3 million in the prior quarter.
  • Over five years, Short term Debt peaked at $18.7 million in Q4 2022 and troughed at $22000.0 in Q4 2023.
  • A 5-year average of $6.4 million and a median of $4.9 million in 2021 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: plummeted 99.88% in 2023 and later skyrocketed 38338.46% in 2025.
  • Year by year, Short term Debt stood at $2.0 million in 2021, then soared by 823.46% to $18.7 million in 2022, then plummeted by 99.88% to $22000.0 in 2023, then grew by 18.18% to $26000.0 in 2024, then skyrocketed by 38338.46% to $10.0 million in 2025.
  • Business Quant data shows Short term Debt for AQST at $10.0 million in Q4 2025, $6.3 million in Q3 2025, and $3.2 million in Q2 2025.